GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » U-Neuron Biomedical Inc (ROCO:6973) » Definitions » Beneish M-Score

U-Neuron Biomedical (ROCO:6973) Beneish M-Score : -2.30 (As of May. 26, 2024)


View and export this data going back to 2023. Start your Free Trial

What is U-Neuron Biomedical Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.3 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for U-Neuron Biomedical's Beneish M-Score or its related term are showing as below:

ROCO:6973' s Beneish M-Score Range Over the Past 10 Years
Min: -2.5   Med: -2.4   Max: -2.3
Current: -2.3

During the past 4 years, the highest Beneish M-Score of U-Neuron Biomedical was -2.30. The lowest was -2.50. And the median was -2.40.


U-Neuron Biomedical Beneish M-Score Historical Data

The historical data trend for U-Neuron Biomedical's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

U-Neuron Biomedical Beneish M-Score Chart

U-Neuron Biomedical Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Beneish M-Score
- - -2.50 -2.30

U-Neuron Biomedical Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Beneish M-Score - - -2.50 - -2.30

Competitive Comparison of U-Neuron Biomedical's Beneish M-Score

For the Biotechnology subindustry, U-Neuron Biomedical's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


U-Neuron Biomedical's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, U-Neuron Biomedical's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where U-Neuron Biomedical's Beneish M-Score falls into.



U-Neuron Biomedical Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of U-Neuron Biomedical for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1172+0.528 * 1.0097+0.404 * 1.7031+0.892 * 1.0087+0.115 * 1.3563
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.8538+4.679 * -0.060564-0.327 * 0.4832
=-2.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was NT$2.38 Mil.
Revenue was NT$27.02 Mil.
Gross Profit was NT$21.56 Mil.
Total Current Assets was NT$489.87 Mil.
Total Assets was NT$523.17 Mil.
Property, Plant and Equipment(Net PPE) was NT$15.09 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$6.96 Mil.
Selling, General, & Admin. Expense(SGA) was NT$34.57 Mil.
Total Current Liabilities was NT$25.67 Mil.
Long-Term Debt & Capital Lease Obligation was NT$4.90 Mil.
Net Income was NT$-84.89 Mil.
Gross Profit was NT$0.00 Mil.
Cash Flow from Operations was NT$-53.21 Mil.
Total Receivables was NT$2.11 Mil.
Revenue was NT$26.79 Mil.
Gross Profit was NT$21.58 Mil.
Total Current Assets was NT$173.77 Mil.
Total Assets was NT$186.30 Mil.
Property, Plant and Equipment(Net PPE) was NT$8.73 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$6.53 Mil.
Selling, General, & Admin. Expense(SGA) was NT$18.49 Mil.
Total Current Liabilities was NT$22.52 Mil.
Long-Term Debt & Capital Lease Obligation was NT$0.00 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(2.379 / 27.023) / (2.111 / 26.789)
=0.088036 / 0.078801
=1.1172

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(21.58 / 26.789) / (21.56 / 27.023)
=0.805555 / 0.797839
=1.0097

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (489.866 + 15.091) / 523.169) / (1 - (173.769 + 8.725) / 186.302)
=0.034811 / 0.02044
=1.7031

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=27.023 / 26.789
=1.0087

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(6.534 / (6.534 + 8.725)) / (6.963 / (6.963 + 15.091))
=0.428206 / 0.315725
=1.3563

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(34.57 / 27.023) / (18.487 / 26.789)
=1.279281 / 0.690097
=1.8538

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((4.896 + 25.665) / 523.169) / ((0 + 22.524) / 186.302)
=0.058415 / 0.1209
=0.4832

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-84.891 - 0 - -53.206) / 523.169
=-0.060564

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

U-Neuron Biomedical has a M-score of -2.30 suggests that the company is unlikely to be a manipulator.


U-Neuron Biomedical Beneish M-Score Related Terms

Thank you for viewing the detailed overview of U-Neuron Biomedical's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


U-Neuron Biomedical (ROCO:6973) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
U-Neuron Biomedical Inc is engaged in research and development of stem cell storage & separation technology, and treatment application technology. It has patent on the Technology of Culture and Isolation of Amniotic Fluid Stem Cell.

U-Neuron Biomedical (ROCO:6973) Headlines

No Headlines